Evaluation of Important Molecular Pathways and Candidate Diagnostic Biomarkers of Noninvasive to Invasive Stages in Gastric Cancer by In Silico Analysis

Tutunchi, Sara; Akhavan, Saeedeh; Bereimipour, Ahmad; Hossein Ghaderian, Sayyed Mohammad

doi:https://doi.org/10.1155/2021/5571413

Journal of Oncology

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusion Data Availability Conflicts of Interest References Copyright Related Articles

Research Article | Open Access

Volume 2021 | Article ID 5571413 | https://doi.org/10.1155/2021/5571413

Evaluation of Important Molecular Pathways and Candidate Diagnostic Biomarkers of Noninvasive to Invasive Stages in Gastric Cancer by In Silico Analysis

Sara Tutunchi,¹Saeedeh Akhavan,²Ahmad Bereimipour,^3,4and Sayyed Mohammad Hossein Ghaderian⁵

Academic Editor: Cristina Magi-Galluzzi

Received21 Feb 2021

Accepted22 Apr 2021

Published11 May 2021

Abstract

Gastric cancer affects millions of people each year; it is the fifth deadliest cancer globally. Due to failure to perform routine tests such as endoscopy, it is usually diagnosed in the invasive stages. Therefore, finding diagnostic biomarkers in blood can help to speed up the initial diagnosis of cancer. This study aimed to find appropriate diagnostic biomarkers in the extracellular matrix of noninvasive to invasive stages of gastric cancer patients, using bioinformatics analysis. First, we selected the appropriate datasets from the GEO database. We evaluated the genes’ signaling pathways, biological processes, and molecular functions. More accurately, we assessed the genes, in which their protein products are released into the extracellular matrix; we evaluated their protein network. Then, we validated the candidate proteins in the GEPIA and TCGA databases. The extracellular matrix, tyrosine kinase receptors, and immune response pathways are effective factors, which are related to the highly expressed genes and metabolism; cell cycle pathways are also impressive on low-expression genes. 69 highly expressed proteins are released into the extracellular matrix. After drawing the protein network, 5 proteins were selected as more suitable candidates for further studies. These proteins’ expression significantly increases in the human samples, and the survival chart showed up to about 80% mortality in the individuals over time. With integrated bioinformatics analysis, BGN, LOX, MMP-9, SERPINE1, and TGFB1 proteins have been selected as suitable diagnostic biomarkers for noninvasive to invasive stages of gastric cancer. Further studies are needed to evaluate more precise mechanisms between these proteins.

1. Introduction

Gastric cancer is one of the most important and life-threatening cancers in the world. It is the fifth common cancer, which affects about 1.5 million people in the world annually. On the contrary, it has several risk factors; one of the most important is Helicobacter pylori infection, which is a common disease among people worldwide [1, 2].

The patients’ age is a treatment challenge. The average age of gastric cancer patients is over 40; even in many countries, it starts from the age of 70 [3, 4]. Also, developing countries do not make timely diagnosis for gastric cancer due to the lack of regular use of diagnostic tests to examine the gastrointestinal tract, such as endoscopy and photofluorography; so the cancer becomes apparent in the invasive stages [5].

Therefore, the initial diagnosis can be checked using more straightforward screening methods, by finding biomarkers in patients’ blood. Then, diagnostic tests can be performed. In this regard, bioinformatics techniques are an effective way to study and select genes and their protein products in various diseases [6, 7], such as cancer; they have made acceptable progress. This study analyzed the gene expression profile in noninvasive to invasive stages of gastric cancer using appropriate datasets. Finally, we further investigated the genes and protein products, which play a significant role in the extracellular matrix.

2. Materials and Methods

2.1. Selecting the Appropriate Dataset

Using the GEO database, we selected the appropriate dataset. GSE84437 microarray dataset contains 433 samples, which have been classified according to the pathological staging, from the primary to the invasive stage of the disease. The platform of this dataset is GPL6947 Illumina HumanHT-12 V3.0 expression BeadChip. This section examined the patients with gastric cancer in the two separate groups of noninvasive and invasive stage. In Figure 1, one can see more information about this database.

(a)

(b)

(c)

(d)

2.2. Preparation of the Data for Bioinformatics Analysis

Using the GEO database and the GEO2R tool, we isolated the gene expression profiles between the noninvasive and invasive stage of gastric cancer. Then, we uploaded the genes into an Excel file and categorized the high- and low-expressed genes. In this part, was considered as the statistically significant level; no limit was set for LogFC. No expression differentiation ranges were applied to the genes clustering in the study.

2.3. Finding Signaling Pathways and Gene Ontologies

For this step, we uploaded the high- and low-expressed genes separately into the Enrichr database: KEGG and Reactome libraries were used to isolate the signaling pathways from the gene clusters. To examine the gene ontology, we used the GO library in the Enrichr and PANTHER databases. Then, we used the ShinyGO database to draw the interaction network of the gene ontology.

2.4. Measuring the Relationship between the Protein Products

We used the STRING database to study the protein products of the genes. Then, we examined the proteins, which were most related to each other, at the center of the protein network.

2.5. Confirmation of Candidate Genes in the Gastric Cancer Samples

To more accurately confirm the selected genes from the previous steps and especially the relationship between the protein network, the final genes were evaluated in the GEPIA database; it uses the TCGA and GTEx databases to examine the gene expression in patients’ samples. Survival and gene expression diagrams were drawn as box plot; they were illustrated by the GEPIA database.

3. Results

3.1. Examination of the Expression of Differential Genes in the Period between the Noninvasive and Invasive Stage of Gastric Cancer

The categorized genes’ expression profile showed 1347 high-expressed and 3281 low-expressed genes. For this evaluation, 10 patients in the noninvasive and invasive stage were selected based on the pathological stage; their expression profiles were evaluated. The data quality and classification performed in the PCA diagram are shown in Figure 1. The highest gene expression was related to MYH11 (LogFC: 2.925856), THBS4 (LogFC: 2.6688873), COL8A1 (LogFC: 2.5590963), CNN1 (LogFC: 2.43792), and GREM1 (LogFC: 2.4140408). The lowest gene expression was related to PGC (LogFC: −4.2971564), LIPF (LogFC: −3.534097), PGA5 (LogFC: −3.4814338), GKN1 (LogFC: −3.4252579), and PGA3 (LogFC: −3.3898602).

Signaling pathways of the extracellular matrix, tyrosine kinase receptors, immune response, metabolism, and cell cycle were significantly observed in the invasive and noninvasive stage of gastric cancer.

After examining the high- and low-expressed genes in the Enrichr database, the following factors were found to be more prominent: the extracellular matrix, assembly of collagen fibrils and other multimeric structures, receptor tyrosine kinases, clathrin-mediated endocytosis, signaling by NOTCH3, interleukins and immune system, membrane trafficking, and semaphorin interaction signaling pathways in the high-expressed genes and the cell cycle, metabolism of proteins, translation, processing of capped intron-containing pre-mRNA, cellular responses to external stimuli, mitochondrial translation, and separation of sister chromatids’ signaling pathways in the low-expressed genes. Figure 2 shows the number of genes involved in each of the signaling pathways separately.

(a)

(b)

3.2. Gene Ontology in Noninvasive and Invasive Gastric Cancer

Different approaches have examined the genes’ nature. In this section, genes were evaluated by three approaches including biological processes, molecular functions, and cellular components. As one can see in Table 1 and Figure 3, biological processes and molecular functions were studied with more focus. Anatomical structure morphogenesis, regulation of the cellular component organization, regulation of the developmental process, actin filament-based process, multicellular organismal process, and vasculature development pathways in biological processes and cytoskeletal protein binding, actin binding, enzyme binding, extracellular matrix structural constituent, cell adhesion molecule binding, and kinase binding in molecular functions with high expression were observed among them.

(a)

(b)

RNA processing, organonitrogen compound biosynthetic process, mitotic cell cycle, cellular response to stress, and peptide metabolic process in biological processes and nucleic acid binding, structural constituent of the ribosome, transferase activity, mRNA binding, and small-molecule binding in molecular functions were observed in the bioinformatics data of low-expressed genes. In the cellular components, the focus was on the 69 involved genes in the extracellular matrix. They have been shown in Figure 4(a).

(a)

(b)

3.3. The Correlation of the Extracellular Matrix Protein Network in the Noninvasive to Invasive Gastric Cancer

In this part of the study, a significant protein network was obtained between the genes, in which their protein products were released into the extracellular matrix. This protein network had 69 nodes, 380 edges, and protein-protein interaction enrichment ( value: <1.0E − 16). Based on the analyses performed by the STRING database, it was found that these genes play an effective role in the ECM-receptor interaction, focal adhesion, TGF-beta, and the PI3K-Akt signaling pathway. In Figure 4(b), one can see more detailed information on how proteins are related and their associated pathways. Accordingly, in this section, the proteins with the most connection with other proteins in the network were selected; the selected proteins are as follows: BGN, LOX, MMP-9, SERPINE1, and TGFB1.

3.4. Candidate Genes Significantly Showed Higher Expression in the Patients with Gastric Cancer

We evaluated the identification of hub genes and protein products, which play a significant role in gastric cancer’s invasive state using the GEPIA database. The expression of BGN, LOX, MMP-9, SERPINE1, and TGFB1 proteins was significantly higher in the samples of gastric cancer patients compared to the healthy people. The survival chart for cited proteins showed 60–80% mortality increment in patients with gastric malignancy (Figure 5); it indicated the importance of these genes’ role.

(a)

(b)

(c)

(d)

(e)

4. Discussion

Identifying the gastric cancer biomarkers can improve the process of diagnosis and treatment. Usually, a high percentage of people in a community do not undergo endoscopic and photofluorography tests, unless they have a specific digestive problem [8, 9]. Also, because the average age of patients with gastric cancer is 40, many people do not desire to perform these tests routinely [10]. For this reason, careful examination and biomarkers’ selection in the body secretions such as blood, saliva, or urine can be helpful in the first step of analysis in the gastric cancer candidates.

In this study, in the first step, bioinformatics analysis could help to predict the candidacy of effective diagnostic biomarkers in gastric cancer. In addition, the gene expression profile of individuals was evaluated in the noninvasive to invasive stage of gastric cancer. In the first step, the associated signaling pathways of gastric cancer invasion were obtained.

One of the important signaling pathways of cancer cell metastasis is the NOTCH3 pathway, which is one of the main angiogenesis actors, but this gene works in many other ways and can facilitate the invasion of cancer cells [11]. The study by Kang et al. showed a direct link between NOTCH3 and Jagged2; NOTCH3 is effective in the development and recurrence of gastric cancer [12]. A study by Wu et al., which assessed patients with gastric cancer, showed that 4 NOTCH receptors play an effective role in stimulating gastric cancer tumor cells; they can be selected as a prognostic biomarker in gastric cancer [13]. Another study by Du et al., a meta-analysis of 1547 gastric cancer patients and 450 control samples, showed higher expression of NOTCH1, NOTCH3, and Jagged1 in the cancer samples than healthy individuals [14]. In general, more studies are needed to find NOTCH3-related pathways in increasing gastric cancer invasion.

One of the most attractive signaling pathways observed in this study was the semaphorin pathway. The semaphorin protein family plays a major role in axonal guidance in neurons. Still, several studies have shown that these neurotransmitters can also play a role in the growth, division, and migration of cancer cells. In a survey by Miyato et al., it was shown that increased SEMA3C expression is directly related to the increased invasion of gastric cancer cells [15]. Maejima et al.’s study also indicated that increased SEMA3E expression could play a key role in the development and metastasis of the gastric cancer cells [16].

The study by Pan et al., who worked on the gastric cancer cell line SGC7901, showed that SEMA5A was significantly overexpressed in these cells and effectively invades them [17]. Then, siRNAs decrease SEMA5A expression, which significantly reduces angiogenesis and metastasis in these cells; on the contrary, it increases the apoptosis induction. Another intriguing study again by Pan et al. showed that SEMA5A could affect MMP-9 by acting on the MEK/ERK pathway and could play a key role in gastric cell invasion [18]. Another study revealed the SEMA5A important role in metastasis and invasion of gastric cancer cells by uPA regulatory activity and the PI3K/Akt pathway [19]. These studies showed that the semaphorin family of proteins play a key role in the nervous system and can also be effective in the cancer development and progression.

To select a suitable biomarker with a bioinformatics approach, it is better to evaluate the high-expressed genes more carefully and observe which protein products of these genes release into the extracellular matrix [20]. Then, in the next steps, the path and the mechanism of these genes or their protein products can be confirmed, and the appropriate strategies can be achieved for timely detection. This study selected the BGN, LOX, MMP-9, SERPINE1, and TGFB1 proteins with more and more accurate relationships in different signaling pathways based on this method. The drawn protein network shows the critical connection between these proteins and other proteins.

Lysyl oxidase (LOX) was one of the selected proteins in this study. It plays a vital role in organizing the ECM by regulating posttranslational processes in fibrous proteins, such as elastin and collagen [21]. Several studies have examined LOX in gastric cancer. Zhao et al. identified a significant association between LOX and MMP-2 and MMP-9 in the gastric cancer cell line and tumor tissue. Decreased expression of MMP-2 and MMP-9 was also observed in the presence of inhibited LOX [22]. The study by Han et al. also showed that increased LOX expression was directly related to HIF-1; increased expression of this gene indicated the hypoxia role in increasing the activity of tumor cells in gastric cancer [23].

Kasashima et al. expressed the inhibition of LOX by siRNAs could reduce E-cadherin expression and increase vimentin expression, thereby activating the EMT pathway [24]. The EMT pathway is one of the most key and effective pathways to enhance the growth, proliferation, and invasion of tumor cells [25]. Zhang et al.’s study also showed that even after surgery in patients with gastric cancer and tumor tissue isolation, LOX expression was high, which led to the recurrence of the disease [26]. Based on the bioinformatics analysis in this study, it was also shown that LOX expression was significantly higher in patients with gastric cancer. Also, according to the survival chart, individuals’ survival decreases significantly over time, which might indicate the key role of this gene in the invasion of gastric tumor cells.

Another studied gene was BGN. It is a member of the proteoglycan group and is leucine rich, which plays a role in regulating fibrous proteins such as elastin and collagen fibers [27]. A study by Hu et al. showed that high BGN expression could play a role in metastasis and invasion of gastric cells into lymph nodes in both laboratory and animal phases. To induce gastric cell invasion, BGN also stimulates the FAK/paxillin signaling pathway, which significantly increases metastasis [28]. Other studies have been performed on BGN and gastric cancer, most notably in bioinformatics analysis; they have related gastric cancer patients with healthy individuals. High expression of BGN is found in gastric cancer [29, 30]. The present study examined the noninvasive to invasive stage of gastric cancer; BGN was found by examining the ECM proteins. As one can see in Figure 5, the survival graph for BGN also decreases dramatically over time.

SERPINE1 in the extracellular matrix revealed another gene association with the noninvasive to invasive stage of gastric cancer. This gene plays an essential role in the cell adhesion, migration of tumor cells to other organs, and cellular aging [31]. The study by He et al. showed that SERPINE1 inhibition using long noncoding RNAs reduces the invasion of gastric tumor cells significantly [32]. Transcriptome studies have shown that SERPNE1 can play an important role in the EMT pathway [33]. Based on the survival chart obtained from this gene, it can be concluded that mortality is directly related to other candidate genes due to increased expression of SERPNE1 and mortality in gastric cancer patients.

Matrix metalloproteinase plays a significant role in the invasion of cancer cells. To date, numerous studies have proven the effective role of this family to invade cancer cells in many malignancies [34]. However, an interesting examined relationship in this study was the role of semaphorin and LOX with MMP-9; these two different signaling pathways can play an important regulatory role for MMP-9.

The study by Wang et al. also showed that MMP-9 is effectively involved in the EMT pathway in gastric cancer. When melatonin was used, the IL-1β/NF-κB/MMP-2/MMP-9 genes’ expression and also invasion of gastric cancer cells reduced significantly [35]. Due to the crucial role of MMP-9 in ECM regeneration, it seems that several factors are associated with this gene. HOXC6, as an important transcription factor, enhances the MMP-9 activity and is involved in increasing the metastasis of gastric cancer [36]. Also, the RUNX3 signaling pathway regulating TIMP3 can be effective in MMP-9 activity in gastric cancer invasion [37].

In association with TGFB1 in gastric cancer, there are limited studies on this gene’s biomarker role. Most studies are about the mutations, variants, and polymorphisms of TGFB1 with gastric cancer. For example, the C-509T [38] and 509C/T [39] mutations were significantly associated with gastric cancer invasion. Therefore, in this study, by performing bioinformatics analysis, we showed that TGFB1 could also be considered as a diagnostic biomarker for gastric cancer.

5. Conclusion

Finally, it can be mentioned that, with the help of continuous bioinformatics analyses, BGN, LOX, MMP-9, SERPINE1, and TGFB1 proteins enhance the progression of gastric cancer; they play a significant role in the organization and communication of cells in the extracellular matrix. Also, a closer look at the mechanism of action between semaphorin, LOX, and MMP-9 can reveal new pathways in gastric cancer invasion and its association with the EMT pathway.

Data Availability

We selected the appropriate datasets from the GEO database. We evaluated the genes’ signaling pathways, biological processes, and molecular functions more accurately.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

P. Rawla and B. Adam, “Epidemiology of gastric cancer: global trends, risk factors and prevention,” Gastroenterology Review, vol. 14, no. 1, 2019.
View at: Publisher Site | Google Scholar
N. Bostanshirin, A Bereimipour, M. Ali Pahlevan Neshan et al., “The regulatory role of exosomal CagA and microRNAs derived from H. pylori-related gastric cancer cells on signaling pathways related to cancer development: a bioinformatics aspect,” Comparative Clinical Pathology, vol. 29, no. 6, pp. 1295–1312, 2020.
View at: Publisher Site | Google Scholar
F. Rashid, T. Thangarajah, D. Mulvey, M. Larvin, and S. Y. Iftikhar, “A review article on gastric volvulus: a challenge to diagnosis and management,” International Journal of Surgery, vol. 8, no. 1, pp. 18–24, 2010.
View at: Publisher Site | Google Scholar
K. Rawicz-Pruszyński, J. W. V. Sandick, J. Mielko, W. P. Polkowski, J. W. Van Sandick, and W. P. Polkowski, “Current challenges in gastric cancer surgery: European perspective,” Surgical Oncology, vol. 27, no. 4, pp. 650–656, 2018.
View at: Publisher Site | Google Scholar
S. A. Abate, “The challenge of screening for early gastric cancer in China,” The Lancet, vol. 388, no. 10060, p. 2606, 2016.
View at: Publisher Site | Google Scholar
Y. Jung, S. Lee, H.-S. Choi et al., “Clinical validation of colorectal cancer biomarkers identified from bioinformatics analysis of public expression data,” Clinical Cancer Research, vol. 17, no. 4, pp. 700–710, 2011.
View at: Publisher Site | Google Scholar
J. H. Phan, R. A. Moffitt, T. H. Stokes et al., “Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment,” Trends in Biotechnology, vol. 27, no. 6, pp. 350–358, 2009.
View at: Publisher Site | Google Scholar
R. Lambert, “Endoscopy in screening for digestive cancer,” World Journal of Gastrointestinal Endoscopy, vol. 4, no. 12, pp. 518–525, 2012.
View at: Publisher Site | Google Scholar
M. Leja, W. You, M. C. Camargo, and H. Saito, “Implementation of gastric cancer screening—the global experience,” Best Practice and Research: Clinical Gastroenterology, vol. 28, no. 6, pp. 1093–106, 2014.
View at: Publisher Site | Google Scholar
M. Song, C. S. Rabkin, and M. C. Camargo, “Gastric cancer: an evolving disease,” Current Treatment Options in Gastroenterology, vol. 16, no. 4, pp. 561–569, 2018.
View at: Publisher Site | Google Scholar
S. Lin, A. Negulescu, S. Bulusu et al., “Non-canonical NOTCH3 signalling limits tumour angiogenesis,” Nature Communications, vol. 8, pp. 1–12, 2017.
View at: Publisher Site | Google Scholar
H. Kang, H.-J. An, J.-Y. Song et al., “Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression,” Histopathology, vol. 61, no. 4, pp. 576–586, 2012.
View at: Publisher Site | Google Scholar
X. Wu, W. Liu, T. Ding, H. Xiao, Z. Wu, and C. Chen, “Prognostic values of four notch receptor MRNA expression in gastric cancer,” Scientific Reports, vol. 6, no. 1, pp. 1–9, 2016.
View at: Publisher Site | Google Scholar
X. Du, Z. Cheng, Y.-H. Wang et al., “Role of notch signaling pathway in gastric cancer: a meta-analysis of the literature,” World Journal of Gastroenterology, vol. 20, no. 27, pp. 9191–9199, 2014.
View at: Publisher Site | Google Scholar
H. Miyato, N. H. Tsuno, and J. Kitayama, “Semaphorin 3C is involved in the progression of gastric cancer,” Cancer Science, vol. 103, no. 11, pp. 1961–1966, 2012.
View at: Publisher Site | Google Scholar
R. Maejima, K. Tamai, T. Shiroki et al., “Enhanced expression of semaphorin 3E is involved in the gastric cancer development,” International Journal of Oncology, vol. 49, no. 3, pp. 887–894, 2016.
View at: Publisher Site | Google Scholar
G. Pan, H. Lv, H. Ren et al., “Elevated expression of semaphorin 5A in human gastric cancer and its implication in carcinogenesis,” Life Sciences, vol. 86, no. 3-4, pp. 139–144, 2010.
View at: Publisher Site | Google Scholar
G. Pan, X. Zhang, and J. Ren, “Semaphorin 5A, an axon guidance molecule, enhances the invasion and metastasis of human gastric cancer through activation of MMP9,” Pathology & Oncology Research, vol. 19, no. 1, pp. 11–18, 2013.
View at: Publisher Site | Google Scholar
G. Pan, Z. Zhu, J. Huang, and C. Yang, “Semaphorin 5A promotes gastric cancer invasion/metastasis via urokinase-type plasminogen activator/phosphoinositide 3-kinase/protein kinase B,” Digestive Diseases and Sciences, vol. 58, no. 8, pp. 2197–2204, 2013.
View at: Publisher Site | Google Scholar
S. Tyanova and J. Cox, “Perseus: a bioinformatics platform for integrative analysis of proteomics data in cancer research,” Methods in Molecular Biology,Cancer Systems Biology, vol. 1711, pp. 133–148, 2018.
View at: Publisher Site | Google Scholar
R. Laczko and K. Csiszar, “Lysyl oxidase (LOX): functional contributions to signaling pathways,” Biomolecules, vol. 10, no. 8, p. 1083, 2020.
View at: Publisher Site | Google Scholar
L. Zhao, H. Niu, Y. Liu et al., “LOX inhibition downregulates MMP-2 and MMP-9 in gastric cancer tissues and cells,” Journal of Cancer, vol. 10, 2019.
View at: Publisher Site | Google Scholar
Y.-L. Han, L. Chen, R. Qin, G.-Q. Wang, X.-H. Lin, and G.-H. Dai, “Lysyl oxidase and hypoxia-inducible factor 1α: biomarkers of gastric cancer,” World Journal of Gastroenterology, vol. 25, no. 15, pp. 1828–1839, 2019.
View at: Publisher Site | Google Scholar
H. Kasashima, M. Yashiro, and H. Kinoshita, “Lysyl oxidase is associated with the epithelial—mesenchymal transition of gastric cancer cells in hypoxia,” Gastric Cancer, vol. 19, no. 2, pp. 431–442, 2016.
View at: Publisher Site | Google Scholar
M. Suarez-Carmona, J. Lesage, D. Cataldo, and C. Gilles, “EMT and Inflammation: inseparable actors of cancer progression,” Molecular Oncology, vol. 11, pp. 805–823, 2017.
View at: Publisher Site | Google Scholar
Q. Zhang, X.-S. Jin, Z.-Y. Yang et al., “Upregulated expression of LOX is a novel independent prognostic marker of worse outcome in gastric cancer patients after curative surgery,” Oncology Letters, vol. 5, no. 3, pp. 896–902, 2013.
View at: Publisher Site | Google Scholar
N. V. Vo, R. A. Hartman, P. R. Patil et al., “Molecular mechanisms of biological aging in intervertebral discs,” Journal of Orthopaedic Research, vol. 34, no. 8, pp. 1289–1306, 2016.
View at: Publisher Site | Google Scholar
L. Hu, Y.-T. Duan, J.-F. Li et al., “Biglycan enhances gastric cancer invasion by activating FAK signaling pathway,” Oncotarget, vol. 5, no. 7, 2014.
View at: Publisher Site | Google Scholar
S. Hu, P. Li, C. Wang, and X. Liu, “Prognostic value of biglycan in gastric cancer,” Researchsquare, pp. 1–22, 2020.
View at: Google Scholar
C. Sun, Y. Qi, D. Wu, X. Meng, and B. Wang, “Identification of core genes and outcome in gastric cancer using bioinformatics analysis,” Oncotarget, vol. 8, no. 41, pp. 70271–70280, 2017.
View at: Publisher Site | Google Scholar
T. M. Simone, C. E. Higgins, R.-P. Czekay et al., “SERPINE1: a molecular switch in the proliferation-migration dichotomy in wound- “activated” keratinocytes,” Advances in Wound Care, vol. 3, no. 3, pp. 281–290, 2014.
View at: Publisher Site | Google Scholar
W. He, D. Zhang, D. Li et al., “Knockdown of long non-coding RNA LINC00200 inhibits gastric cancer progression by regulating MiR-143-3p/SERPINE1 axis,” Digestive Diseases and Sciences, Article ID 0123456789, 2020.
View at: Publisher Site | Google Scholar
B. Xu, Z. Bai, J. Yin, and Z. Zhang, “Global transcriptomic analysis identifies SERPINE1 as a prognostic biomarker associated with epithelial-to-mesenchymal transition in gastric cancer,” PeerJ, vol. 7, Article ID e7091, pp. 1–23, 2019.
View at: Publisher Site | Google Scholar
A. Castro-castro, V. Marchesin, A. Castro-castro et al., “Cellular and molecular mechanisms of MT1-MMP-dependent cancer cellular and molecular mechanisms of MT1-MMP-dependent cancer cell invasion,” The Annual Review of Cell and Developmental Biology, vol. 32, pp. 555–576, 2015.
View at: Publisher Site | Google Scholar
X. Wang, B. Wang, W. Zhan, L. Kang, S. Zhang, and C. Chen, “Biomedicine & pharmacotherapy melatonin inhibits lung metastasis of gastric cancer in vivo,” Biomedicine & Pharmacotherapy, vol. 117, Article ID 109018, 2019.
View at: Publisher Site | Google Scholar
S.-W. Chen, Q. Zhang, Z.-F. Xu et al., “HOXC6 promotes gastric cancer cell invasion by upregulating the expression of MMP9,” Molecular Medicine Reports, vol. 14, no. 4, pp. 3261–3268, 2016.
View at: Publisher Site | Google Scholar
Y. Chen, X. Wei, C. Guo et al., “Runx3 suppresses gastric cancer metastasis through inactivation of MMP9 by upregulation of TIMP-1,” International Journal of Cancer, vol. 1598, pp. 1586–1598, 2011.
View at: Publisher Site | Google Scholar
H. J. Kim, M. Kwon, N. Kim, J. B. Lee, and S. Won, “The influence of family history on stage and survival of gastric cancer according to the TGFB1 C-509T polymorphism in korea,” Gut Liver, vol. 14, no. 1, pp. 79–88, 2020.
View at: Publisher Site | Google Scholar
L. Xu, Z. Zeng, B. Chen et al., “Association between the TGFB1 -509C/T and TGFBR2 -875A/G polymorphisms and gastric cancer: a case-control study,” Oncology Letters, vol. 2, no. 2, pp. 371–377, 2011.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2021 Sara Tutunchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

529

Downloads

833

Citations